Authors: Dong Zheng Jian Ma Yong Yu Minghui Li Rui Ni Grace Wang Ruizhen Chen Jianmin Li GuoChang Fan James C Lacefield Tianqing Peng
Publish Date: 2015/05/21
Volume: 58, Issue: 8, Pages: 1949-1958
Abstract
MicroRNAs miRs have been suggested as potential therapeutic targets for heart diseases Inhibition of miR195 prevents apoptosis in cardiomyocytes stimulated with palmitate and transgenic overexpression of miR195 induces cardiac hypertrophy and heart failure We investigated whether silencing of miR195 reduces diabetic cardiomyopathy in a mouse model of streptozotocin STZinduced type 1 diabetesMiR195 expression was increased and levels of its target proteins B cell leukaemia/lymphoma 2 and sirtuin 1 were decreased in STZinduced type 1 and db/db type 2 diabetic mouse hearts Systemically delivering an antimiR195 construct knocked down miR195 expression in the heart reduced caspase3 activity decreased oxidative stress attenuated myocardial hypertrophy and improved myocardial function in STZinduced mice with a concurrent upregulation of B cell leukaemia/lymphoma 2 and sirtuin 1 Diabetes reduced myocardial capillary density and decreased maximal coronary blood flow in mice Knockdown of miR195 increased myocardial capillary density and improved maximal coronary blood flow in diabetic mice Upregulation of miR195 sufficiently induced apoptosis in cardiomyocytes and attenuated the angiogenesis of cardiac endothelial cells in vitro Furthermore inhibition of miR195 prevented apoptosis in cardiac endothelial cells in response to NEFA an important feature of diabetesTherapeutic silencing of miR195 reduces myocardial hypertrophy and improves coronary blood flow and myocardial function in diabetes at least in part by reducing oxidative damage inhibiting apoptosis and promoting angiogenesis Thus miR195 may represent an alternative therapeutic target for diabetic heart diseases
Keywords: